APRE.US Aprea Therapeutics Inc

Healthcare Biotechnology USA Stocks
0.4322 USD
Close of Nov 13, 2026
0.4100 1.29
Market cap
USD 6.13M
P/E
-
P/B
0.18x
ROE
-45.7%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.

Is APRE.US undervalued?

Graham number

The Graham number of Aprea Therapeutics Inc cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Aprea Therapeutics Inc fundamental analysis

No fundamental analysis for Aprea Therapeutics Inc yet.

Aprea Therapeutics Inc stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Aprea Therapeutics Inc

Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel synthetic lethality-based cancer therapeutics that targets DNA damage response pathways. Its lead product candidates are APR-1051, an orally bioavailable small-molecule inhibitor of WEE1 kinase that is in Phase 1 clinical trial for the treatment of patients with advanced solid tumors with biomarkers and ATRN-119, an ATR inhibitor, which is in Phase 1/2a clini…

Full company profile